KKR agrees to buy Medicover's India hospitals for €1.2 billion

KKR agreed to buy Medicover’s India hospital business for €1.2 billion, a deal that would deepen the U.S. buyout firm’s exposure to one of the world’s fastest-growing healthcare markets. The transaction is still subject to regulatory approvals, including clearance from India’s Competition Commission.

The sale gives KKR a larger platform in India’s hospital sector, where demand for private healthcare, diagnostics and specialty services has risen alongside income growth, urbanization and the need for modern medical infrastructure. Medicover’s Indian operations were described in related coverage as a multi-specialty hospital network, a footprint that makes the asset valuable to a global buyer looking for scale, brand strength and local reach.

For Medicover, the divestment can free up capital and sharpen the company’s focus on other parts of its business. For KKR, the timing fits a broader pattern of private-equity firms pursuing healthcare assets that can generate stable cash flow and long-term growth, even as broader market conditions remain unsettled. India’s hospital market has kept drawing cross-border capital because it combines rising demand with room for network expansion, especially in large urban centers and fast-growing regional cities.

The transaction also stands out because of its size. The deal ranks among the bigger healthcare transactions in India, where foreign investment has often run into regulatory hurdles and the operational complexity of building and running hospital infrastructure. That backdrop helps explain why ownership changes in hospital chains matter beyond the balance sheet: new owners can alter capital spending plans, management priorities and the pace at which hospitals add beds, specialties and new locations.

Patients, workers and competitors will be watching how KKR approaches the business if the acquisition is approved. Higher ownership concentration can bring more investment into equipment, technology and facilities, but it can also intensify pressure on pricing and raise questions about how aggressively a private-equity owner will push growth. The deal signals that large global funds still see Indian healthcare as a durable investment story, even with policy risk, pricing pressure and execution challenges built into the sector.